Cervical cancer prevention & the role of human papillomavirus vaccines in India

Indian Journal of Medical Research

Volumn 130, Issue 3, 2009, Pages 334-340

  Bhatla, Neerja ^a   Joseph, Elizabeth ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Cervical cancer; Human papillomavirus; Like particle; Prophylactic vaccine; Virus

Indexed keywords

CAPSID PROTEIN; NEUTRALIZING ANTIBODY; PLACEBO; WART VIRUS VACCINE;

CANCER MORTALITY; CANCER SCREENING; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY; DRUG COST; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EARLY DIAGNOSIS; ELECTROSURGERY; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; INDIA; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MYALGIA; PATIENT SELECTION; PRECANCER; PRIMARY PREVENTION; PROTECTION; PRURITUS; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS CARCINOGENESIS; WART VIRUS;

FEMALE; HUMANS; INDIA; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 72649089299     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Bhatla N, Lal N, Bao YP, Ng T, Qiao YL. A meta-analysis of human papillomavirus type-distribution in women from south Asia: implications for vaccination. Vaccine 2008; 26: 2811-7.
2. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88: 63-73.
3. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095-101.
4. Bhatla N, Ramakrishna S, Virmani A, Arora VK, Gulati A, et al. Correlation of FastHPV and cytology: Performance trial results from India. Paper presented at 24th International Papillomavirus Conference and Clinical workshop, Beijing, November 3-9, 2007.
5. Dillner J. The serological response to papillomaviruses. Semin Cancer Biol 1999; 9: 423-30.
6. Wikstrom A, van Doornum GJ, Kirnbauer R, Quint WG, Dillner J. Prospective study on the development of antibodies against human papillomavirus type 6 among patients with condyloma acuminata or new asymptomatic infection. J Med Virol 1995; 46: 368-74.
7. Hagensee ME, Olson NH, Baker TS, Galloway DA. Three- dimensional structure of vaccinia virus-produced human papillomavirus type-1 capsids. J Virol 1994; 68: 4503-5.
8. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh Desmarquet C, Orth G, et al. Immunization with virus-like particles in cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69: 3959-63.
9. Kirnbauer R, Chandrachud LM, O'Neil BW, Wagner ER, Grindlay GJ, Armstrong A, et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 1996; 219: 37-44.
10. Roden RB, Hubbert NL, Kirnbauer R, Christensen ND, Lowy DR, Schiller JT. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol 1996; 70: 3298-301.
11. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56: 1-24.
12. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006; 107: 18-27.
13. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-65.
14. Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006; 24: 5571-83.
15. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-55.
16. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-27.
17. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95: 1459-66.
18. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-43.
19. th International Papillomavirus Conference and Clinical workshop, Beijing, November 3-9, 2007.
20. th International Papillomavirus Conference and Clinical workshop, Beijing, November 3-9, 2007.
21. Franco E, Cuzick J, Hildesheim A, de Sanjose S. Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006; 24: S171-7.
22. th Biennial Meeting of the International Gynae Cancer Society, Bangkok, October 2008.
23. Available from: Vaccine_Investment_Strategy.pdf www.gavialliance.org/.../3, accessed on August 16, 2009.
24. Available from: www.who.int/vaccinesdocuments/DocsPDF/www9825.pdwww.gavialliance.org/.../3, accessed on August 16, 2009.
25. Madhivanan P, Krupp K, Yashodha MN, Marlow L, Klausner JD, Reingold AL. Attitudes toward HPV vaccination among parents of adolescent girls in Mysore, India. Vaccine 2009; 27: 5203-8.
26. Available from: http://www.who.int/vaccines/globalsummary/immunization/countryprofileresult.cfm, accessed on November 1, 2008.
27. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 278-85.
28. Coeshott CM, Smithson SL, Verderber E, Samaniego A, Blonder JM, Rosenthal GJ, et al. Pluronic F127-based systemic vaccine delivery systems. Vaccine 2004; 22: 2396-405.
29. Sturesson C, Artursson P, Ghaderi R, Johansen K, Mirazimi A, Uhnoo I, et al. Encapsulation of rotavirus into poly(lactide- coglycolide) microspheres. J Control Release 1999; 59: 377-8.
30. Mossadegh N, Gissmann L, Muller M, Zentgraf H, Alonso A, Tomakidi P. Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells. Virology 2004; 326: 57-66.
31. Jochmus I, Schafer K, Faath S, Muller M, Gissman L. Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine. Arch Med Res 1999; 30: 269-74.
32. Dupuy C, Buzoni-Gatel D, Touze A, Le Cann P, Bout D, Coursaget P. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J Virol 1999; 73: 9063-71.
33. Rose RC, White WI, Li M, Suzich JA, Lane C, Garcea RL. Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virol 1998; 72: 6151-4.